Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein
Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Philip N. Hawkins(The Royal Free Hospital), Laurence Lovat(University College London), Mark B. Pepys(University College London), M.R. Persey(The Royal Free Hospital)
Cited by 601
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2021|1.1k